Mallinckrodt Presents Data on TERLIVAZ ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week ® (DDW)

“ Two poster presentations of Mallinckrodt (OTC:)’s research for adults with HRS with rapid reduction in kidney function¹  provide further insight into treatment with TERLIVAZ for appropriate patients “

DUBLIN, May 18, 2024 /PRNewswire/ — Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ ^® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function¹ at the 2024 Digestive Disease Week ^® (DDW) taking place in Washington, DC from May 18-21, 2024.

The posters feature a post-hoc analysis of data from the pivotal Phase III CONFIRM trial, analyzing the impact of dose interruptions on treatment response to TERLIVAZ in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI),² and a pooled analysis of three Phase III clinical studies assessing the impact of TERLIVAZ treatment on patients with HRS and a baseline serum creatinine (SCr) 3

TERLIVAZ is the first and only FDA-approved product indicated to improve kidney function in adults with HRS with rapid reduction in kidney function,¹ an acute and life-threatening condition requiring hospitalization.⁴ HRS involving rapid reduction in kidney function¹ is estimated to affect more than 42,000 Americans annually and rates of hospitalizations are increasing.⁵

Please see Limitation of Use and Important Safety Information, including Boxed Warning, below.

“We’re excited to present our research at DDW. It represents our ongoing commitment to add to the depth and breadth of data on TERLIVAZ and its important role in the treatment of adult patients with HRS with rapid reduction in kidney function,”¹ said Peter Richardson, MRCP (UK), Executive Vice President & Chief Scientific Officer. “Collectively, these data support our understanding of those who are most likely to benefit from TERLIVAZ showing the potential impact of use in the real-world, including when the dosing schedule is interrupted.”  

Abstract #4025396: Treatment Response to Terlipressin is Unaffected by Dose Interruptions in Patients with Hepatorenal Syndrome-Acute Kidney Injury²

• Presenter:  Khalid Mumtaz, MD, The Ohio State University Wexner Medical Center, Columbus, OH
• Session Type:  Poster Presentation
• Session  Portal Hypertension and Other Complications of Cirrhosis
• Session Date and Time:  Saturday, May 18, 2024;  12:30  “  1:30 p.m. EDT

This analysis evaluated the effect of dose interruption on the incidence of HRS…